Archive | April, 2020

Life Science Nation (LSN) Welcomes AdvaMed Members to the Digital Redefining Early Stage Investments (RESI) Partnering Event April 29th & 30th

16 Apr

200+ Medical Device, Diagnostic and Digital Health Investment Partners Will Virtually Gather @ Digital RESI

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

AdvaMed has partnered with Life Science Nation, the creator of the Digital Redefining Early Stage Investments (RESI) conference, to facilitate access for AdvaMed members to the upcoming Digital RESI 2-Day Partnering Event on April 29th – 30th

This partnering event will give AdvaMed members a chance to interact with 200+ investors and strategic partners, view their investment interests and request a 30-minute meeting that will be hosted on an integrated videoconferencing system. The digital partnering event will take place over 2 full days across four continents, from home offices, at any time you and the investment partner are available. The partnering software will synch up disparate time zones based on availability of each attendee’s meeting schedule.

AdvaMed members can also get additional visibility in the Featured Company Forum, having their own landing page on the conference website. If you are an AdvaMed member, please reach out to RESI@lifesciencenation.com for a discount code to register.

NEW! Featured Company Forum

16 Apr

By Gregory Mannix, Chief Conference Officer, Vice President International Business Development, LSN

As we have announced, April marks a new milestone for the RESI Conference Series with our first ever Digital RESI 2-Day Partnering Event taking place at the end of the month. Not being a full RESI conference means there is no Pitch Sessions, Innovation Challenge or Investor Panels, but companies who wish to get greater visibility can showcase their technology in our new Featured Company Forum on the event website. Your company logo in the Forum will redirect interested parties to your own landing page, allowing you to highlight your company with your 1-page data sheet, Executive Summary, Pitch Deck, etc.  See an example below.

If you are registered for the April event, you can add your company to the Forum for $250 Click Here to Apply.

Apply for the Digital RESI Innovation Challenge

16 Apr

By Karen Deyo, Senior Investor Research Analyst, LSN

Our Digital RESI taking place on June 8-10th is just around the corner, and companies will once again be able to showcase their technologies through the RESI Innovation Challenge. Companies can apply to participate, and the review team will use the LSN Expert System to select the 30 most ‘investable’ companies to be featured. Each company will have their own dedicated site to present their poster digitally, as well as any other non-confidential material they wish to share. These companies will compete for votes among RESI attendees, with the top three companies winning prizes. Click here to complete the application. Don’t wait too long, as the application deadline is May 6th!

 

 

 

 

Hot Investor Mandate: USA Family Office Seeks Worldwide Opportunities in Medical Technology and Consumer Health

16 Apr

This family office is an investment fund associated with an industrial engineering firm. The firm invests in and incubates new technologies in the medical device and consumer health sectors. The firm is highly flexible in terms of investment structure, focusing on opportunities in which their engineering and commercialization expertise can provide a value-add. The firm’s investments may include equity financing, services such as prototyping and design, and other structures such as royalties. The firm will invest worldwide.

The family office focuses on medical technology and consumer health, including devices, diagnostics, sterilization, blood testing, sensors, MRI/Radiation machines, and home health products. The firm is a multi-stage investor, and has worked with entrepreneurs as early as idea-stage. The firm invests in all classes of medical device including PMA opportunities.

The family office is focused on investing in companies in which the firm’s expertise is a relevant value-add.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Venture Arm of Hong Kong Family Office Actively Invests in Therapeutics, Medical Device, Diagnostics Startups and Healthcare Services with Strong China Market Potential

16 Apr

A venture arm of an investment firm founded by a family office in Hong Kong is focused on making early stage life science investments across sectors such as new therapeutics, diagnostics, medical devices, medical/healthcare services, healthcare IT and more. The firm is managed by a team of investment professionals who are entrepreneurial, have deep scientific and industry knowledge and are effective in the environment in which they operate.

The firm seeks to invest in new therapeutics, diagnostics, medical devices, medical/healthcare services, healthcare IT and etc. For therapeutics, the firm seeks novel small molecule and biologics and is agnostic in terms of indication. However, indications that address a large market in China are of interest. The firm looks for early stage assets in pre-clinical and phase I of clinical trials. However, the firm will not rule out assets in phase II. For devices, the firm is opportunistic in terms of the class of device.

The firm seeks an active role in its portfolio companies and generally obtain a seat on the board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: UK-Based Private Investment Firm Seeks Therapeutics Companies with Particular Interest in Metabolic Diseases, Immunology, Aging and Infectious Diseases Indications

16 Apr

A private life science investment firm has a presence in U.K, Canada and multiple locations in U.S. The firm looks to make investments into privately held companies and while the firm can be flexible in terms of allocation size, most investments fall in the $0.5 – 3 million range. The firm is open to investing in companies located around the globe.

The firm is currently looking for therapeutics companies across all indication areas with particular attention to metabolic diseases (including type II diabetes), immune-oncology, aging, and infectious diseases. The firm is interested in pre-clinical stage companies that have a lead asset established as well as companies in early clinical trials. The firm is open to all molecule types that meet this criteria. The firm is generally not interested in next generation cytotoxic chemotherapies, therapies for Alzheimer’s Disease, or therapies for cardiovascular indications.

The firm is a hands-on investor who contribute substantially to the operation of their portfolio companies, often supplementing management with a network of drug developers and specialists in regulatory affairs, clinical affairs, manufacturing, and other subspecialties.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: China-Based, US-Specialized VC Seeks Opportunities in Early Stage to Pre-IPO Across All Life Science & Healthcare Industries

16 Apr

A specialized US venture capital firm under a holding group company focuses on finance, conducting business with its Chinese sister company as one group. The firm has headquarters in China and an additional virtual office in the U.S. The firm is actively seeking investment opportunities from early stage to pre-IPO rounds. The average size of investment is ~ $5M. The firm has invested in 17 US & Canada companies since 2016. The firm can act as the lead investor or co-investor depends on different cases, and the firm prefers to have a board seat.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, and Diagnostics. The firm will also consider orphan drugs and digital health companies. The firm is open to all kinds of sectors. The firm is open to medical devices with all FDA regulatory pathways, including 510k and PMA. The firm is open to any phases in medical devices and therapeutics. However, the firm will invest in private companies only.

The firm has no specific requests on the management team. The firm generally takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →